Olanzapine monotherapy in posttraumatic stress disorder: Efficacy in a randomized, double-blind, placebo-controlled study

Simple item page
dc.contributor.authorCarey P.
dc.contributor.authorSuliman S.
dc.contributor.authorGanesan K.
dc.contributor.authorSeedat S.
dc.contributor.authorStein D.J.
dc.date.accessioned2012-08-13T07:45:13Z
dc.date.available2012-08-13T07:45:13Z
dc.date.issued2012
dc.descriptionArticle
dc.description.abstractObjectives Although there have been important advances in the treatment of posttraumatic stress disorder (PTSD), many patients fail to respond to first-line pharmacotherapy. Limited evidence suggests that second generation antipsychotics may have a role to play as monotherapy in PTSD. Methods We undertook a randomized, placebo-controlled study using flexible-dose olanzapine monotherapy for 8 weeks in 28 adult male and female participants (mean age: 40.75 ± 11.59 years) with non-combat related chronic PTSD. Data were analysed with repeated measures analysis of variance, using an intention to treat, last observation carried forward approach. Results The olanzapine group (n = 14) demonstrated significantly greater improvement on the Clinician Administered PTSD Scale from baseline to endpoint than the placebo group (n = 14) (F = 5.71, p = 0.018). Olanzapine was generally well tolerated, with no serious adverse events recorded. Substantial weight gain (6-10 kg) was, however, reported in 6/14 participants in the olanzapine group. Conclusions To our knowledge, this is the first controlled evidence of the efficacy of olanzapine monotherapy in an exclusively non-combat related chronic PTSD group. Despite the small sample size, these data suggest that olanzapine may have a role in the treatment of PTSD. These findings warrant replication in a larger sample. Copyright © 2012 John Wiley & Sons, Ltd. Copyright © 2012 John Wiley & Sons, Ltd.
dc.identifier.citationHuman Psychopharmacology
dc.identifier.citation27
dc.identifier.citation4
dc.identifier.citation386
dc.identifier.citation391
dc.identifier.issn8856222
dc.identifier.otherdoi:10.1002/hup.2238
dc.identifier.urihttp://hdl.handle.net/10019.1/49193
dc.subjectolanzapine
dc.subjectposttraumatic stress disorder
dc.subjectrandomized controlled trial
dc.titleOlanzapine monotherapy in posttraumatic stress disorder: Efficacy in a randomized, double-blind, placebo-controlled study
Files
Collections
Stellenbosch University - Scopus Publications